Project finance for new hospitals and major expansion, term loans for pharma manufacturing capex (US-FDA, EU-GMP compliant), and working capital for pharma exporters. Strong expertise across Hyderabad, Mumbai, Ahmedabad pharma clusters.
BIG LOANS arranges ₹100 crore-and-above debt for Indian healthcare & pharma — across hospital project finance (greenfield and major expansion), pharma manufacturing capex (US-FDA, EU-GMP compliant facilities, formulation plants, API units), and working capital and ECB for pharma exporters. The Indian pharma cluster is concentrated in Hyderabad (Dr Reddy's, Aurobindo, Divis, Hetero), Mumbai (Sun Pharma, Lupin, Glenmark, Cipla), and Ahmedabad (Zydus, Torrent, Intas). Hospital finance has long moratoriums (matching cash-flow ramp); pharma manufacturing requires regulatory diligence beyond standard TEV.
Healthcare debt splits cleanly into two sub-sectors. Hospitals (Apollo, Fortis, Max, Manipal, Narayana, Medanta) — long moratoriums (3-5 years post-COD) because patient volume ramps slowly; cash flow modelled on bed occupancy, ALOS, ARPOB; specialized lenders.
Pharma manufacturing requires regulatory diligence beyond standard TEV — US-FDA observation history, GMP compliance, validation timelines, batch records. Lenders often appoint specialist pharma consultants alongside the standard TEV team. Pricing reflects export profile (50%+ FX revenue) and regulatory standing.
Common funding situations across healthcare & pharma.
Greenfield hospital construction — multi-specialty, tertiary care, single-specialty. ₹250-1,500 Cr project finance with 3-5 year moratorium.
New US-FDA approved facility, formulation plant, API unit. ₹250-2,000 Cr project finance with regulatory diligence overlay.
Pharma exporters with US/EU/Japan revenue. Packing credit + post-shipment + receivable financing for ₹100-500 Cr.
ECB at SOFR + spread for natural-hedge pharma exporters. 200-300 bps below rupee debt typical.
Multi-hospital expansion plan for established chains. Acquisition finance for hospital acquisitions + greenfield additions.
R&D infrastructure, regulatory compliance upgrades, FDA remediation capex.
Healthcare and pharma have distinct product fit.
Healthcare and pharma require sector expertise. Most major lenders have dedicated pharma desks; hospital finance is more specialized.
SBI, BOB, Indian Bank, Canara — dedicated pharma lending desks with TEV partnerships.
HDFC, ICICI, Axis — competitive for pharma exporters and established hospital chains.
StanChart, HSBC, DBS, MUFG — heavily active for pharma exporter ECB, particularly via Hyderabad and Mumbai.
Active for pharma growth capex, R&D financing, and hospital acquisition finance.
Limited specialist NBFCs but growing — particularly active for mid-sized hospital chains.
Same 5-stage process for any large-ticket corporate debt mandate, applied to healthcare & pharma specifics.
NDA, then a short call to understand the business model, key financial drivers, capital need. Sector-specific risk factors mapped early.
Optimal facility mix, tenor, security. Lender shortlist tuned to sector appetite — banks for vanilla, NBFCs / AIFs for specialty structures.
Sector-grade Information Memorandum, financial model, market analysis. Pitched to shortlisted lenders in parallel.
Multiple sanctions negotiated in parallel on pricing, covenants, security. Final lender(s) selected.
Loan agreement, security creation, CPs satisfied, drawdown. Sector-specific compliances (RERA, FEMA, SEBI, etc.) handled along the way.
Share a one-page brief on your business and funding need. We respond within one working day with feasibility, structuring and lender shortlist tuned to your sector.